S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
In a recent transaction, Corey Michael Watton, a director at Zevra Therapeutics, Inc. (NASDAQ:ZVRA), purchased 300 shares of the company’s common stock. The shares were acquired on March 28, 2025, at a price of $7.8384 per share, totaling approximately $2,351. The purchase price was near the stock’s current trading level of $7.49, with the stock showing significant volatility over the past year, trading between $4.20 and $9.76. Following this transaction, Watton’s direct ownership in the company increased to 1,800 shares. This move reflects Watton’s continued investment in Zevra Therapeutics, a company known for its focus on pharmaceutical preparations. According to InvestingPro data, while the company maintains strong liquidity with a current ratio of 2.53, analysts project continued growth but don’t expect profitability this year. For deeper insights into insider trading patterns and 10+ additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Zevra Therapeutics reported a net loss of $35.7 million for the fourth quarter of 2024, translating to a loss of $0.67 per share, which was below analyst expectations of a $0.40 loss per share. However, the company’s revenue for the quarter was $12 million, surpassing the forecasted $8.52 million, primarily driven by strong sales of MIPLYFFA. JMP Securities responded to these results by raising Zevra’s stock target to $18, citing the company’s strong U.S. sales performance. Meanwhile, Canaccord Genuity also updated its outlook, increasing its price target for Zevra to $25 and maintaining a Buy rating, reflecting confidence in the company’s future sales estimates and strategic plans.
Cantor Fitzgerald reiterated its Overweight rating on Zevra with a $25 price target, highlighting the successful transition of patients from the Expanded Access Program to commercial drug use. The firm expressed optimism about Zevra’s ongoing efforts to identify and diagnose patients with Niemann-Pick disease type C. Zevra’s financial standing at the end of 2024 included $75.5 million in cash reserves, with plans to extend its cash runway into 2029. The company anticipates additional financial gains from the sale of its priority review voucher, which could further bolster its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.